8 active not recruiting, 7 completed, 6 recruiting, 5 terminated. 17 Phase 2, 15 Phase 1, 1 Phase 3, 1 Phase 4.
Follow nirogacestat: new trials by email Literature Review of nirogacestat trials Research Report on nirogacestat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nirogacestat in Patients With Kaposi Sarcoma Biospecimen Collection, Chest Radiography, Computed Tomography - AIDS-Related Kaposi Sarcoma, Skin Kaposi Sarcoma | Phase 2 | Recruiting | AIDS Malignancy Consortium | 28 | 2026-10-13 | 2026-10-20 |
| To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants Nirogacestat, Nirogacestat and Cocktail of CYP Specific Probe Substrates - Healthy | Phase 1 | Completed | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 20 | 2025-10-27 | 2026-05-01 |
| Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) Nirogacestat - Desmoid Tumor, Aggressive Fibromatosis | Phase 4 | Recruiting | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 50 | 2025-09-17 | 2026-10-13 |
| Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole - Healthy | Phase 1 | Completed | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 24 | 2025-08-21 | 2026-05-08 |
| A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) Nirogacestat oral tablet - Desmoid Tumor, Aggressive Fibromatosis | Phase 2 | Active not recruiting | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 20 | 2025-08-08 | 2026-09-15 |
| Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study Nirogacestat - Tumor | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-11-26 | 2026-08-10 |
| Study of Cryoablation and Nirogacestat for Desmoid Tumor Nirogacestat, Cryoablation - Desmoid Tumor | Phase 2 | Recruiting | Nam Bui | 28 | 2023-08-15 | 2026-09-10 |
| A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma Belantamab Mafodotin-Blmf, Lenalidomide, Dexamethasone - Multiple Myeloma, Neoplasms | Phase 1 / Phase 2 | Recruiting | Hellenic Society of Hematology | 36 | 2023-07-14 | 2023-10-24 |
| A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment Belantamab Mafodotin, Nirogacestat, Pomalidomide - Multiple Myeloma | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 9 | 2022-10-04 | 2026-07-21 |
| Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM Belantamab mafodotin, Nirogacestat, Pomalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 14 | 2022-08-31 | 2026-06-25 |
| Nirogacestat in Ovarian Granulosa Cell Tumors Nirogacestat - Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor | Phase 2 | Completed | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 53 | 2022-08-30 | 2026-08-25 |
| A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments Linvoseltamab, Daratumumab, Carfilzomib - Multiple Myeloma | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 317 | 2022-08-17 | 2026-07-08 |
| Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM Belantamab mafodotin, Nirogacestat, Lenalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 20 | 2022-07-19 | 2026-06-16 |
| MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma Elranatamab + Nirogacestat, Elranatamab + lenalidomide + dexamethasone - Multiple Myeloma | Phase 2 | Terminated | Pfizer | 46 | 2021-10-27 | 2026-04-24 |
| A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma Teclistamab, Daratumumab, Pomalidomide - Multiple Myeloma | Phase 1 | Active not recruiting | Janssen Research & Development, LLC | 140 | 2021-03-12 | 2026-09-28 |
| A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery Biospecimen Collection, Computed Tomography, Echocardiography Test - Desmoid Fibromatosis, Recurrent Desmoid Fibromatosis | Phase 2 | Active not recruiting | Children's Oncology Group | 31 | 2020-10-07 | 2026-10-01 |
| Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM Belantamab mafodotin, Nirogacestat - Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 106 | 2020-06-08 | 2026-05-06 |
| A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma PBCAR269A, Fludarabine, Cyclophosphamide - Relapsed/Refractory Multiple Myeloma | Phase 1 | Terminated | Precision BioSciences, Inc. | 48 | 2020-04-30 | 2023-09-21 |
| Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) Belantamab mafodotin, GSK3174998, Feladilimab - Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 208 | 2019-10-07 | 2026-05-06 |
| Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) ALLO-715, ALLO-647, Fludarabine - Relapsed/Refractory Multiple Myeloma | Phase 1 | Completed | Allogene Therapeutics | 73 | 2019-09-23 | 2026-05-13 |
Showing 20 of 31. Sign in to see all of them.
Multiple Myeloma (11) · Desmoid Tumors (8) · Neoplasms (3) · AIDS-related Kaposi sarcoma (2) · Blood Protein Disorders (1) · Breast Neoplasms (1) · Corneal Diseases (1) · Granulosa cell tumor of the ovary (1) · HIV Infections (1) · Hematologic Diseases (1) · Leukemia (1) · Neoplasms by Histologic Type (1) · Neoplasms, Plasma Cell (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1)
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (7) · Pfizer (6) · GlaxoSmithKline (4) · AIDS Malignancy Consortium (2) · Allogene Therapeutics (1) · Children's Oncology Group (1) · Hellenic Society of Hematology (1) · Janssen Research & Development, LLC (1) · Jules Bordet Institute (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Nam Bui (1) · National Cancer Institute (NCI) (1) · Precision BioSciences, Inc. (1) · Regeneron Pharmaceuticals (1)
United States (23) · Canada (8) · France (7) · Germany (6) · Spain (6) · Belgium (5) · Greece (5) · Italy (5) · Netherlands (5) · Poland (5) · South Korea (4) · United Kingdom (4) · Australia (3) · Brazil (3) · Mexico (3)
Lee Ratner (2) · Bernd Kasper, MD (1) · Evangelos Terpos, Prof (1) · Fariba Navid (1) · Geraldine H O'Sullivan Coyne, M.D. (1) · Jeroen van de Wetering, MD (1) · Keila Torres, MD,PHD (1) · Malin Hultcrantz, MD, PhD (1) · Mary Beth Brune, MD (1) · Michail Ignatiadis, MD, PhD (1)
PMID 23511909, PMID 26407235, PMID 28350521, PMID 33682447, PMID 33730360, PMID 36884323, PMID 37347393, PMID 39584380, PMID 41115259, PMID 41518037
2023 (6), 2014 (2), 2025 (1), U01CA121947 (1), U10CA180886 (1), UM1CA121947 (1)